{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:41:56Z","timestamp":1748299316738},"reference-count":27,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Omadacycline is a first-in-class aminomethylcycline antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacterial pathogens. A series of nonclinical studies, including mammalian pharmacologic receptor binding studies, human ether-a-go-go-related gene (hERG) channel binding studies, studies of the effects on\n            <jats:italic>ex vivo<\/jats:italic>\n            sinoatrial (SA) node activity, and studies of\n            <jats:italic>in vivo<\/jats:italic>\n            effects on cardiovascular function in the cynomolgus monkey, was undertaken to assess the cardiovascular risk potential. Omadacycline was found to bind almost exclusively to the muscarinic subtype 2 acetylcholine receptor (M\n            <jats:sub>2<\/jats:sub>\n            ), and in the SA node model it antagonized the effect of a pan-muscarinic agonist (carbamylcholine) in a concentration-dependent manner. Omadacycline exhibited no effect on hERG channel activity at 100 \u03bcg\/ml (179.5 \u03bcM), with a 25% inhibitory concentration of 166 \u03bcg\/ml (298.0 \u03bcM). Omadacycline had no effect on QTc in conscious monkeys at doses up to 40 mg\/kg of body weight. Overall, omadacycline appears to attenuate the parasympathetic influence on the heart rate but has a low potential to induce cardiac arrhythmia or to have clinically significant cardiovascular toxicity.\n          <\/jats:p>","DOI":"10.1128\/aac.00320-16","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T03:08:33Z","timestamp":1466564913000},"page":"5247-5253","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Assessments of Cardiovascular Effects with Omadacycline"],"prefix":"10.1128","volume":"60","author":[{"given":"S. Ken","family":"Tanaka","sequence":"first","affiliation":[{"name":"Paratek Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Villano","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_3_2","volume-title":"Abstr 43rd Intersci Conf Antimicrob Agents Chemother","author":"Bhatia B","year":"2003","unstructured":"Bhatia B, Bowser T, Chen J, Ismail M, McIntyre L, Mechiche R, Nelson M, Ohemeng K, Verma A, Jones G, Fallon M. 2003. PTK 0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant gram-positive bacteria, poster F-755. Abstr 43rd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_4_2","volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Biedenbach DJ","year":"2010","unstructured":"Biedenbach DJ, Mendes RE, Sader HS, Jones RN. 2010. In vitro evaluation of PTK796 activity tested against Staphylococcus aureus, including hospital- and community-associated MRSA strains from the USA and Europe, abstr E-1569. Abstr 50th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_2_7_2","article-title":"A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects, abstr P1423","author":"Sun H","year":"2012","unstructured":"Sun H, Ting L, Maietta R, Machineni S, Praestgaard J, Kuemmell A, Stein DS, Sunkara G, Kovacs SJ, Draper MP. 2012. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects, abstr P1423. Abstr 22nd Eur Congr Clin Microbiol Infect Dis.","journal-title":"Abstr 22nd Eur Congr Clin Microbiol Infect Dis"},{"key":"e_1_3_2_8_2","volume-title":"U.S","author":"U.S. Food and Drug Administration","year":"2005","unstructured":"U.S. Food and Drug Administration. 2005. Guidance for industry. S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. U.S. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706678"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.1.2.121"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.1.122"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1027309703313"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.101881"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.302.1.320"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2001.0835"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705338"},{"key":"e_1_3_2_18_2","volume-title":"Cardiovascular pharmacology concepts","author":"Klabunde RE","year":"2011","unstructured":"Klabunde RE. 2011. Cardiovascular pharmacology concepts. Lippincott Williams & Wilkins, Philadelphia, PA."},{"key":"e_1_3_2_19_2","first-page":"818","article-title":"Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline","volume":"296","author":"Stengel PW","year":"2001","unstructured":"Stengel PW, Cohen ML. 2001. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. J Pharmacol Exp Ther 296:818\u2013824.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_20_2","volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Ting L","year":"2010","unstructured":"Ting L, Sun H, Kovacs SJ, Klausner K, Tanaka SK. 2010. Pharmacokinetics of intravenous and oral PTK796, a new aminomethylcycline antibiotic, abstr K-124. Abstr 50th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_21_2","volume-title":"Abstr 52nd Intersci Conf Antimicrob Agents Chemother","author":"Sun H","year":"2012","unstructured":"Sun H, Ting L, Flarakos J, Dole K, Praestgaard J, Kovacs SJ, Stein DS, Sunkara G, Tanaka SK. 2012. Pharmacokinetics of [14C]-labelled omadacycline (PTK 0796) in healthy male subjects, abstr A-1281. Abstr 52nd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1113"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2008.01.007"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00418-2"},{"key":"e_1_3_2_25_2","volume-title":"Omadacycline, an aminomethylcycline antibiotic, has no effect on QT\/QTc intervals in healthy subjects, abstr P1321","author":"Villano S","year":"2016","unstructured":"Villano S, Tanaka SK. 2016. Omadacycline, an aminomethylcycline antibiotic, has no effect on QT\/QTc intervals in healthy subjects, abstr P1321. Abstr 26th Eur Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.04.074"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"e_1_3_2_28_2","volume-title":"Pharmacological reviews, NDA 21-821","author":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration","year":"2005","unstructured":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration. 2005. Pharmacological reviews, NDA 21-821. U.S. Food and Drug Administration, Rockville, MD."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00320-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00320-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:31:47Z","timestamp":1645475507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00320-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1128\/AAC.00320-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00320-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"2016-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}